Aspyrian raises $40M in series B round

Aspyrian Therapeutics Inc. (San Diego, Calif.) raised $40 million in a series B round from Hiroshi Mikitani, an Aspyrian director. Mikitani is CEO of Japanese e-commerce company Rakuten Inc. (Tokyo:4755).

Aspyrian has an exclusive license to the Photoimmunotherapy platform from NIH's National Cancer Institute (NCI). The technology comprises antibodies conjugated to a photoactivatable molecule. The conjugates can be laser-activated at a tumor site. ...